Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes

Jessica Castle, Julia M. Engle, Joseph El Youssef, Ryan G. Massoud, Kevin C J Yuen, Ryland Kagan, W. Kenneth Ward

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

OBJECTIVE - To minimize hypoglycemia in subjects with type 1 diabetes by automated glucagon delivery in a closed-loop insulin delivery system. RESEARCH DESIGN AND METHODS - Adult subjects with type 1 diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia. Seven subjects received glucagon using high-gain parameters, and six subjects received glucagon in a more prolonged manner using low-gain parameters. Blood glucose levels were measured every 10 min and insulin and glucagon infusions were adjusted every 5 min. All subjects received a portion of their usual premeal insulin after meal announcement. RESULTS - Automated glucagon plus insulin delivery, compared with placebo plus insulin, significantly reduced time spent in the hypoglycemic range (15 ± 6 vs. 40 ± 10 min/day, P = 0.04). Compared with placebo, high-gain glucagon delivery reduced the frequency of hypoglycemic events (1.0 ± 0.6 vs. 2.1 ± 0.6 events/day, P = 0.01) and the need for carbohydrate treatment (1.4 ± 0.8 vs. 4.0 ± 1.4 treatments/day, P = 0.01). Glucagon given with low-gain parameters did not significantly reduce hypoglycemic event frequency (P = NS) but did reduce frequency of carbohydrate treatment (P = 0.05). CONCLUSIONS - During closed-loop treatment in subjects with type 1 diabetes, high-gain pulses of glucagon decreased the frequency of hypoglycemia. Larger and longer-term studies will be required to assess the effect of ongoing glucagon treatment on overall glycemic control.

Original languageEnglish (US)
Pages (from-to)1282-1287
Number of pages6
JournalDiabetes Care
Volume33
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Glucagon
Type 1 Diabetes Mellitus
Hypoglycemia
Insulin
Hypoglycemic Agents
Placebos
Carbohydrates
Therapeutics
Meals
Blood Glucose
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. / Castle, Jessica; Engle, Julia M.; El Youssef, Joseph; Massoud, Ryan G.; Yuen, Kevin C J; Kagan, Ryland; Ward, W. Kenneth.

In: Diabetes Care, Vol. 33, No. 6, 06.2010, p. 1282-1287.

Research output: Contribution to journalArticle

Castle, Jessica ; Engle, Julia M. ; El Youssef, Joseph ; Massoud, Ryan G. ; Yuen, Kevin C J ; Kagan, Ryland ; Ward, W. Kenneth. / Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. In: Diabetes Care. 2010 ; Vol. 33, No. 6. pp. 1282-1287.
@article{25d5d8e8b71c43b1a66be7afe2622f52,
title = "Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes",
abstract = "OBJECTIVE - To minimize hypoglycemia in subjects with type 1 diabetes by automated glucagon delivery in a closed-loop insulin delivery system. RESEARCH DESIGN AND METHODS - Adult subjects with type 1 diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia. Seven subjects received glucagon using high-gain parameters, and six subjects received glucagon in a more prolonged manner using low-gain parameters. Blood glucose levels were measured every 10 min and insulin and glucagon infusions were adjusted every 5 min. All subjects received a portion of their usual premeal insulin after meal announcement. RESULTS - Automated glucagon plus insulin delivery, compared with placebo plus insulin, significantly reduced time spent in the hypoglycemic range (15 ± 6 vs. 40 ± 10 min/day, P = 0.04). Compared with placebo, high-gain glucagon delivery reduced the frequency of hypoglycemic events (1.0 ± 0.6 vs. 2.1 ± 0.6 events/day, P = 0.01) and the need for carbohydrate treatment (1.4 ± 0.8 vs. 4.0 ± 1.4 treatments/day, P = 0.01). Glucagon given with low-gain parameters did not significantly reduce hypoglycemic event frequency (P = NS) but did reduce frequency of carbohydrate treatment (P = 0.05). CONCLUSIONS - During closed-loop treatment in subjects with type 1 diabetes, high-gain pulses of glucagon decreased the frequency of hypoglycemia. Larger and longer-term studies will be required to assess the effect of ongoing glucagon treatment on overall glycemic control.",
author = "Jessica Castle and Engle, {Julia M.} and {El Youssef}, Joseph and Massoud, {Ryan G.} and Yuen, {Kevin C J} and Ryland Kagan and Ward, {W. Kenneth}",
year = "2010",
month = "6",
doi = "10.2337/dc09-2254",
language = "English (US)",
volume = "33",
pages = "1282--1287",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes

AU - Castle, Jessica

AU - Engle, Julia M.

AU - El Youssef, Joseph

AU - Massoud, Ryan G.

AU - Yuen, Kevin C J

AU - Kagan, Ryland

AU - Ward, W. Kenneth

PY - 2010/6

Y1 - 2010/6

N2 - OBJECTIVE - To minimize hypoglycemia in subjects with type 1 diabetes by automated glucagon delivery in a closed-loop insulin delivery system. RESEARCH DESIGN AND METHODS - Adult subjects with type 1 diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia. Seven subjects received glucagon using high-gain parameters, and six subjects received glucagon in a more prolonged manner using low-gain parameters. Blood glucose levels were measured every 10 min and insulin and glucagon infusions were adjusted every 5 min. All subjects received a portion of their usual premeal insulin after meal announcement. RESULTS - Automated glucagon plus insulin delivery, compared with placebo plus insulin, significantly reduced time spent in the hypoglycemic range (15 ± 6 vs. 40 ± 10 min/day, P = 0.04). Compared with placebo, high-gain glucagon delivery reduced the frequency of hypoglycemic events (1.0 ± 0.6 vs. 2.1 ± 0.6 events/day, P = 0.01) and the need for carbohydrate treatment (1.4 ± 0.8 vs. 4.0 ± 1.4 treatments/day, P = 0.01). Glucagon given with low-gain parameters did not significantly reduce hypoglycemic event frequency (P = NS) but did reduce frequency of carbohydrate treatment (P = 0.05). CONCLUSIONS - During closed-loop treatment in subjects with type 1 diabetes, high-gain pulses of glucagon decreased the frequency of hypoglycemia. Larger and longer-term studies will be required to assess the effect of ongoing glucagon treatment on overall glycemic control.

AB - OBJECTIVE - To minimize hypoglycemia in subjects with type 1 diabetes by automated glucagon delivery in a closed-loop insulin delivery system. RESEARCH DESIGN AND METHODS - Adult subjects with type 1 diabetes underwent one closed-loop study with insulin plus placebo and one study with insulin plus glucagon, given at times of impending hypoglycemia. Seven subjects received glucagon using high-gain parameters, and six subjects received glucagon in a more prolonged manner using low-gain parameters. Blood glucose levels were measured every 10 min and insulin and glucagon infusions were adjusted every 5 min. All subjects received a portion of their usual premeal insulin after meal announcement. RESULTS - Automated glucagon plus insulin delivery, compared with placebo plus insulin, significantly reduced time spent in the hypoglycemic range (15 ± 6 vs. 40 ± 10 min/day, P = 0.04). Compared with placebo, high-gain glucagon delivery reduced the frequency of hypoglycemic events (1.0 ± 0.6 vs. 2.1 ± 0.6 events/day, P = 0.01) and the need for carbohydrate treatment (1.4 ± 0.8 vs. 4.0 ± 1.4 treatments/day, P = 0.01). Glucagon given with low-gain parameters did not significantly reduce hypoglycemic event frequency (P = NS) but did reduce frequency of carbohydrate treatment (P = 0.05). CONCLUSIONS - During closed-loop treatment in subjects with type 1 diabetes, high-gain pulses of glucagon decreased the frequency of hypoglycemia. Larger and longer-term studies will be required to assess the effect of ongoing glucagon treatment on overall glycemic control.

UR - http://www.scopus.com/inward/record.url?scp=77956071742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956071742&partnerID=8YFLogxK

U2 - 10.2337/dc09-2254

DO - 10.2337/dc09-2254

M3 - Article

C2 - 20332355

AN - SCOPUS:77956071742

VL - 33

SP - 1282

EP - 1287

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -